37.67

0.11% 0.04

Pre-market: 38.50 0.83 +2.20%

Akero Therapeutics Inc (AKRO)

Overview News Price History Option Chain Financials Why AKRO Down? Discussions Forecast

Akero Therapeutics Inc stock is traded at $37.67, with a volume of 884.04K. It is up +0.11% in the last 24 hours and down -16.70% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Previous Close:

$37.63

Open:

$37.28

24h Volume:

884.04K

Relative Volume:

0.65

Market Cap:

$2.99B

Revenue:

Net Income/Loss:

$-237.22M

P/E Ratio:

-9.9656

EPS:

-3.78

Net Cash Flow:

$-212.64M

1W Performance:

+0.19%

1M Performance:

-16.70%

6M Performance:

+21.91%

1Y Performance:

+81.45%

1-Day Range:

$37.28

$39.59

1-Week Range:

$36.46

$39.59

52-Week Range:

$17.86

$58.40

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name

Akero Therapeutics Inc

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

650-487-6488

Address

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Employee

Twitter

@akerotx

Next Earnings Date

2024-11-11

Latest SEC Filings

AKRO's Discussions on Twitter

Compare AKRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKRO Akero Therapeutics Inc	37.67	2.99B	0	-237.22M	-212.64M	-3.78
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-25	Upgrade	BofA Securities	Neutral → Buy
Jan-27-25	Reiterated	H.C. Wainwright	Buy
Nov-18-24	Initiated	Citigroup	Buy
Apr-22-24	Resumed	BofA Securities	Neutral
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight
Aug-28-23	Initiated	UBS	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-10-21	Initiated	BofA Securities	Buy
Feb-26-21	Initiated	Guggenheim	Buy
Sep-10-20	Initiated	Morgan Stanley	Overweight
Jul-20-20	Reiterated	H.C. Wainwright	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy
Jul-01-20	Reiterated	H.C. Wainwright	Buy
Mar-02-20	Initiated	H.C. Wainwright	Buy
Feb-10-20	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Evercore ISI	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight
Jul-15-19	Initiated	Jefferies	Buy
Jul-15-19	Initiated	ROTH Capital	Buy

View All

Akero Therapeutics Inc Stock (AKRO) Latest News

Apr 21, 2025

Walleye Capital LLC Buys New Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 21, 2025

Apr 20, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com

Apr 20, 2025

Apr 19, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Geode Capital Management LLC - MarketBeat

Apr 19, 2025

Apr 18, 2025

University of Wisconsin Foundation Has $11.42 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 18, 2025

Catriona Yale Sells 9,073 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat

Apr 18, 2025

8,336 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Optimize Financial Inc - MarketBeat

Apr 18, 2025